Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Coelho, Lara ^a   Cardoso, Sandra Wagner ^a   Amancio, Rodrigo Teixeira ^a   Moreira, Ronaldo Ismério ^a   Campos, Dayse Pereira ^a   Veloso, Valdiléa Gonçalves ^a   Grinsztejn, Beatriz ^a   Luz, Paula Mendes ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; ATYPICAL MYCOBACTERIUM; BRAZIL; CD4 LYMPHOCYTE COUNT; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; DEVELOPING COUNTRY; ESOPHAGUS CANDIDIASIS; FEMALE; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; ISOSPORIASIS; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PNEUMOCYSTIS PNEUMONIA; PULMONARY CRYPTOCOCCOSIS; RURAL POPULATION; TOXOPLASMOSIS; TREND STUDY; TUBERCULOSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; FACTUAL DATABASE; FOLLOW UP; HISTORY; HIV INFECTIONS; IMMUNOLOGY; VIROLOGY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BRAZIL; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; INCIDENCE; MALE;

EID: 84902521742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098666     Document Type: Article

References (47)

1. Akolo C, Adetifa I, Shepperd S, Volmink J (2010). Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev(1): Cd000171.
2. Badri M, Maartens G, Bekker LG, Wood R (2005). The spectrum and prognosis of AIDS-defining illnesses in Cape Town. The Southern African Journal of HIV Medicine 6(2): 11-16.
3. Badri M, Wilson D, Wood R (2002). Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359(9323): 2059-2064. (Pubitemid 34680968)
4. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, et al. (1997). Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. Aids 11(14): 1731-1738. (Pubitemid 27470275)
5. Buchacz K, Baker RK, Moorman AC, Richardson JT, Wood KC, et al. (2008). Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. Aids 22(11): 1345-1354.
6. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, et al. (2010). AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. Aids 24(10): 1549-1559.
7. CDC (1991). Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR Recomm Rep 40(RR-5): 27-32.
8. CDC (1992). 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR Recomm Rep 41(RR-17).
9. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T (1992). Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis 146(2): 285-289.
10. Charurat M, Blattner W, Hershow R, Buck A, Zorrilla CD, et al. (2004). Changing trends in clinical AIDS presentations and survival among HIV-1-infected women. J Womens Health (Larchmt) 13(6): 719-730. (Pubitemid 39276364)
11. Coelho L, Veloso VG, Grinsztejn B, Luz PM (2013). Trends in overall opportunistic illnesses, Pneumocystis carinii pneumonia, cerebral toxoplasmosis and Mycobacterium avium complex incidence rates over the 30 years of the HIV epidemic: a systematic review. Brazilian Journal of Infectious Diseases.
12. Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, et al. (2009). III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol 35(10): 1018-1048.
13. Dubey JP, Lago EG, Gennari SM, Su C, Jones JL (2012). Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology 139(11): 1375-1424.
14. Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, et al. (2013). Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 13(10): 852-858.
15. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, et al. (2009). Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. Aids 23(5): 631-636.
16. Grinsztejn B, Hosseinipour M, Ribaudo H, Havlir D, Cohen M, et al. (2014). Effects of Early versus Delayed Initiation of Antiretroviral Therapy on HIV Clinical Outcomes: Results from the HPTN 052. Lancet Infect Dis Accepted.
17. Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, et al. (2013). Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One 8(4): e59768.
18. Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM, et al. (2009). Early mortality and cause of deaths in patients using HAART in Brazil and the United States. Aids 23(16): 2107-2114.
19. Grinsztejn B, Veloso VG, Pilotto JH, Campos DP, Keruly JC, et al. (2007). Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr 45(5): 515-520. (Pubitemid 47294923)
20. Israelski DM, Chmiel JS, Poggensee L, Phair JP, Remington JS (1993). Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr 6(4): 414-418. (Pubitemid 23112853)
21. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, et al. (2000). Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30 Suppl 1: S5-14.
22. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R (2008). Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Aids 22(15): 1897-1908.
23. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, et al. (1999). AID-Srelated opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. Jama 282(23): 2220-2226. (Pubitemid 30002965)
24. Mathews WC, Fullerton SC (1994). Use of a clinical laboratory database to estimate Toxoplasma seroprevalence among human immunodeficiency virus-infected patients. Overcoming bias in secondary analysis of clinical records. Arch Pathol Lab Med 118(8): 807-810. (Pubitemid 24249118)
25. Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, et al. (1999). Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J Acquir Immune Defic Syndr 21(5): 401-407. (Pubitemid 29384002)
26. Mocroft A, Youle M, Phillips AN, Halai R, Easterbrook P, et al. (1998). The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Arch Intern Med 158(5): 491-497. (Pubitemid 128681610)
27. Moreira RI, Luz PM, Struchiner CJ, Morgado M, Veloso VG, et al. (2011). Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore. J Acquir Immune Defic Syndr 57 Suppl 3: S171-178.
28. 47.MS (1994). Co-infecção TB/HIV/AIDS: Manual de Normas. P. N. d. DST/AIDS. Brasilia: 1-20.
29. 12.MS (1999). Terapia Anti-retroviral e Saúde Pública. Um balanço da experiência brasileira.
30. Pacheco AG, Tuboi SH, May SB, Moreira LFS, Ramadas L, et al. (2009). Temporal Changes in Causes of Death Among HIV-Infected Patients in the HAART Era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 51(5): 624-630 610.1097/QAI.1090b1013e3181a1094ecf1095.
31. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338(13): 853-860. (Pubitemid 28135961)
32. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr (1993). Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342(8866): 268-272. (Pubitemid 23224420)
33. Podlasin RB, Wiercinska-Drapalo A, Olczak A, Beniowski M, Smiatacz T, et al. (2006). Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002. Infection 34(4): 196-200. (Pubitemid 44214503)
34. Ribeiro S, Luz PM, Campos D, Moreira R, Japiassu A, et al. (2013). Incidence and determinants of severe morbidity among HIV-infected patients from Rio de Janeiro, Brazil, 2000-2010. Antiviral Therapy.
35. Rojanawiwat A, Tsuchiya N, Pathipvanich P, Pumpradit W, Schmidt W-P, et al. (2011). Impact of the National Access to Antiretroviral Program on the incidence of opportunistic infections in Thailand. International Health 3(2): 101-107.
36. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV (2006). Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 145(6): 397-406. (Pubitemid 46768570)
37. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, et al. (2001). HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56(2): 257-260. (Pubitemid 32095372)
38. San-Andres FJ, Rubio R, Castilla J, Pulido F, Palao G, et al. (2003). Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 36(9): 1177-1185. (Pubitemid 36549641)
39. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M (2002). Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 34(4): 543-546. (Pubitemid 34112278)
40. Schwarcz L, Chen MJ, Vittinghoff E, Hsu L, Schwarcz S (2013). Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. Aids 27(4): 597-605.
41. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, et al. (2010). Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363(3): 257-265.
42. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, et al. (2012). Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 9(7): e1001270.
43. 16.WHO (2007). WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children.
44. 29.WHO (2011). Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings.
45. 11.WHO (2012). Global tuberculosis Report.
46. Xavier GA, Cademartori BG, Cunha Filho NA, Farias NA (2013). Evaluation of seroepidemiological toxoplasmosis in HIV/AIDS patients in the south of Brazil. Rev Inst Med Trop Sao Paulo 55(1): 25-30.
47. Yazdanpanah Y, Chene G, Losina E, Goldie SJ, Merchadou LD, et al. (2001). Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 30(4): 864-871. (Pubitemid 32827397)